Group items tagged

Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.

The global immunotherapy drugs market will continue to grow, owing to increasing incidence of lifestyle-related and chronic disease globally, increasing product approvals, rising healthcare expenditures, and increasing access to better diagnostic & treatment facilities. High preference for immunotherapy over traditional chemotherapy and its use in combination with the same in first-line treatments coupled with high adoption of targeted therapies is expected to support the market growth during the forecast period 2019-2025. The immunotherapy drugs market, by type of drug, is segmented into monoclonal antibodies (mAbs), vaccine, non-specific immunotherapies, adaptive cell therapy, and others. Among these, monoclonal antibodies occupied a significant share in 2018 while the fastest growing type was adaptive cell therapy, which is expected to grow at a high CAGR during the forecast period 2019-2025. Increased preference for mAbs with fewer side-effects made this type the dominant market shareholder in 2018.

Leukemia treatment is rapidly evolving with innovations like targeted therapy, immunotherapy, and stem cell transplants